Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (...
Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series
About this item
Full title
Author / Creator
Publisher
Melbourne: John Wiley & Sons Australia, Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Melbourne: John Wiley & Sons Australia, Ltd
Subjects
More information
Scope and Contents
Contents
Pembrolizumab is the standard first‐line treatment for advanced non‐small cell lung cancer (NSCLC) with programmed death‐ligand 1 (PD‐L1) expression tumor proportion score (TPS) ≥50%. The benefit of pembrolizumab in patients with advanced NSCLC and poor performance status (PS ≥3) is limited, even when the tumor is PD‐L1‐expression‐positive. We retr...
Alternative Titles
Full title
Clinical outcomes of pembrolizumab therapy in advanced‐NSCLC patients with poor performance status (≥3) and high PD‐L1 expression (TPS ≥50%): A case series
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7705620
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7705620
Other Identifiers
ISSN
1759-7706
E-ISSN
1759-7714
DOI
10.1111/1759-7714.13713
